Compare TECH & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TECH | ROIV |
|---|---|---|
| Founded | 1976 | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.5B | 14.1B |
| IPO Year | 1989 | N/A |
| Metric | TECH | ROIV |
|---|---|---|
| Price | $57.01 | $22.87 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 14 | 8 |
| Target Price | ★ $71.23 | $24.31 |
| AVG Volume (30 Days) | 1.8M | ★ 7.4M |
| Earning Date | 02-04-2026 | 11-10-2025 |
| Dividend Yield | ★ 0.56% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.49 | N/A |
| Revenue | ★ $1,216,732,000.00 | $20,329,000.00 |
| Revenue This Year | $2.33 | N/A |
| Revenue Next Year | $7.05 | $376.94 |
| P/E Ratio | $118.01 | ★ N/A |
| Revenue Growth | ★ 3.85 | N/A |
| 52 Week Low | $46.01 | $8.73 |
| 52 Week High | $79.28 | $23.23 |
| Indicator | TECH | ROIV |
|---|---|---|
| Relative Strength Index (RSI) | 38.12 | 71.54 |
| Support Level | $56.59 | $20.14 |
| Resistance Level | $61.20 | $21.48 |
| Average True Range (ATR) | 1.97 | 0.79 |
| MACD | -0.65 | 0.14 |
| Stochastic Oscillator | 4.84 | 85.33 |
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. It reports in two segments: protein sciences (about 75% of revenue) and diagnostics and genomics (25%). The protein sciences segment sells reagents and analytical instruments used in life sciences research, including antibodies used in protein analysis. The diagnostics and genomics segment sells diagnostic reagents, molecular diagnostics, and spatial biology products. The United States accounts for about 55% of revenue. The firm also has operations in Europe, the Middle East, and Africa (20% of sales), the UK (5%), and Asia-Pacific (15%), with the rest of the world accounting for the remaining 5%.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.